Allogene Therapeutics Inc (NAS:ALLO)
$ 2.07 -0.01 (-0.48%) Market Cap: 432.18 Mil Enterprise Value: 138.33 Mil PE Ratio: 0 PB Ratio: 0.76 GF Score: 28/100

Allogene Therapeutics Inc R&D Showcase Transcript

Nov 29, 2022 / 06:00PM GMT
Release Date Price: $9.31 (-9.26%)
David D. Chang
Allogene Therapeutics, Inc. - Co-Founder, President, CEO & Director

It's so great to see so many of you in the room in person. It has been long overdue. Welcome, and thank you for joining us today in our R&D Showcase. As I said, many of you are here in this room, but there are a lot more who are joining us online. My name is David Chang, President and CEO and Co-Founder of Allogene.

Many of us have been immersed in cell therapy and sometimes forget to realize that we are in the early days of creating a new modality that many -- that is unlike any before it. A single infusion that can induce deep and durable responses where we now talk about the possibility of cure, even in the advanced and refractory disease setting.

CD19 CAR T trial had a humble beginning as an investigator-sponsored academic trial in 2019, but quickly gained the momentum as early reports of complete remission were published a few years later. That got the attention of many in biotech, leading to approval of the first autologous CAR T directed therapies at CD19 in 2017, YESCARTA and KYMRIAH.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot